As a result of this, SBIO can now independently drive the development of its lead JAK2 program.
Recent data from phase 2 clinical trials of SB1518 indicated promising clinical efficacy and good tolerability for the treatment of myelofibrosis (MF), an orphan indication with high unmet medical need.
SB1518 has also demonstrated clinical benefits in patients with relapsed/refractory lymphoma.
SBIO plans to advance SB1518 and SB1578 through clinical development, with pivotal trials for SB1518 anticipated to begin later this year.
SBIO CEO Jan-Anders Karlsson said SB1518 has now reached a critical inflection point where its future success in a highly competitive field depends on an aggressive and focused development plan.
"As an existing shareholder, Onyx’s interests remain aligned with SBIO’s objective to maximize the value of the JAK2 program and to share in the upside potential of SB1518 and other SBIO assets," Karlsson said.